Bladder Irritation And Uti Tablet, Chewable
NDC Package 61727-353-60

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Bladder Irritation And Uti (cantharis, clematis, cubeba, echinacea, ranunculus bulbosus, sabal ser, staphysagria, uva ursi) tablets is adult and children 12 years and older: Under 12 consult a doctor. This formulation utilizes a tablet, chewable delivery system. Marketed by Homeocare Laboratories, Inc., this product is identified by NDC 61727-353.

Identification & Billing

NDC Package Code
61727-353-60
Package Description
60 TABLET, CHEWABLE in 1 BOTTLE
Product Code
61727-353
11-Digit Billing Format
61727035360

Clinical Specifications

Proprietary Name
Bladder Irritation And Uti
Non-Proprietary Name
Cantharis, Clematis, Cubeba, Echinacea, Ranunculus Bulbosus, Sabal Ser, Staphysagria, Uva Ursi
Substance Name
Arctostaphylos Uva-ursi Leaf; Clematis Recta Flowering Top; Delphinium Staphisagria Seed; Echinacea Angustifolia; Lytta Vesicatoria; Piper Cubeba Fruit; Ranunculus Bulbosus; Serenoa Repens Whole
Dosage Form
Tablet, Chewable - A solid dosage form containing medicinal substances with or without suitable diluents that is intended to be chewed, producing a pleasant tasting residue in the oral cavity that is easily swallowed and does not leave a bitter or unpleasant after-taste.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Adult and children 12 years and older: Under 12 consult a doctor. Slightly chew one tablet and allow to dissolve in the mouth, 3 times daily or up to 6 times daily for intense symptoms. Reduce to one tablet daily for 7 days after symptoms improve. Take at least 15mn apart from food and drinks

Regulatory & Marketing

Labeler Name
Homeocare Laboratories, Inc.
Product Type
Human Otc Drug
Marketing Category
UNAPPROVED HOMEOPATHIC - A category specifying that a product is marketed as unapproved homeopathic product.
Start Marketing Date
03-19-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61727-353-60 identifies a specific commercial package of 60 tablet, chewable in 1 bottle of Bladder Irritation And Uti, a human over the counter drug labeled by Homeocare Laboratories, Inc.. This tablet, chewable is formulated for oral use and contains arctostaphylos uva-ursi leaf; clematis recta flowering top; delphinium staphisagria seed; echinacea angustifolia; lytta vesicatoria; piper cubeba fruit; ranunculus bulbosus; serenoa repens whole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Homeocare Laboratories, Inc. on March 19, 2019. The current certification is valid through December 31, 2026.

How is this Homeocare Laboratories, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61727035360. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
61727-353-60
11-Digit CMS (5-4-2)
61727-0353-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.